The article provides an overview of analyst ratings for Terns Pharma in the last quarter. While there are more bullish and somewhat bullish ratings than indifferent ones, the overall sentiment is mixed. The average 12-month price target has increased significantly, but it's important to note that analyst ratings are not always accurate predictors of stock performance. Therefore, the short-term impact on TERN's stock price is neutral.